{"page_content": "70\nSASB TOPIC REPORTINGUNIT OF \nMEASURECODE\nNumber of settlements of Abbreviated \nNew Drug Application (ANDA) \nlitigation that involved payments and/\nor provisions to delay bringing an \nauthorized generic product to market \nfor a defined time period\nList of products listed in the Food \nand Drug Administration\u2019s (FDA) \nMedWatch Safety Alerts for Human \nMedical Products databaseAmgen discloses material, legal, and regulatory \nissues in its annual 10-K and quarterly 10-Qs\nSee FDA MedWatch databaseNumber\nn/aHC-BP-240b.1\nHC-BP-250a.1Percentage change in: (1) average \nlist price and (2) average net \nprice across U.S. product portfolio \ncompared to previous year\nNumber of fatalities associated with \nproducts as reported in the FDA \nAdverse Event Reporting SystemPertinent reporting can be found in the Our \nApproach to Pricing, Access and Affordability, \nand Amgen\u2019s Approach to Responsible Pricing \nsections of our website; and the Risk Factors \nand the Management, Discussion and Analysis \nsections of the 10-K and quarterly 10-Qs\nSee FDA Adverse Event Reporting SystemPercentage \n(%)\nNumberHC-BP-240b.2\nHC-BP-250a.2Percentage change in: (1) list \nprice and (2) net price of product \nwith largest increase compared to \nprevious yearPertinent reporting can be found in the Our \nApproach to Pricing, Access and Affordability, \nand Amgen\u2019s Approach to Responsible Pricing \nsections of our website; and the Risk Factors \nand the Management, Discussion and Analysis \nsections of the 10-K and 10-QsPercentage \n(%)HC-BP-240b.3\nAffordability \n& Pricing\nDrug SafetyAPPENDIX INTRODUCTION GOVERNANCECOVID- 19 \nRESPONSEBUSINESS \nETHICSETHICAL \nRESEARCHACCESS TO \nMEDICINEDIVERSITY, INCLUSION, \nAND BELONGINGENVIRONMENTAL\nSUSTAINABILITYRESPONSIBLE \nSOURCINGCOMMUNITY \nINVESTMENT\nACCOUNTING METRIC", "metadata": {"source": "NASDAQ_AMGN_2020.pdf", "page": 69, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}